ACAD - アカディア・ファ―マシュ―ティカルズ (ACADIA Pharmaceuticals Inc.) アカディア・ファ―マシュ―ティカルズ

 ACADのチャート


 ACADの企業情報

symbol ACAD
会社名 Acadia Pharmaceuticals Inc (アカディア・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アカディア・ファーマシューティカルズ(ACADIA Pharmaceuticals Inc.)は神経と関連の中枢神経系疾患における満たされていない医療ニーズに応じた小分子薬事業を中心とするバイオ医薬品会社。同社は第III相開発段階におけるパーキンソン病精神病のためのファーストインクラスの治療薬である「pimavanserin」を含む4種類の製品候補を有する。同社は「pimavanserin」に対してグローバルな販売権を持つ。更に、同社はAllergan Inc.と連携して開発する慢性痛治療用の第II相試験にある薬品候補及び緑内障治療用の第I相試験にある薬品候補を有し、並びにMeiji Seika Kaisha Ltdと連携して開発する統合失調症治療用第I相開発段階における薬品候補も有する。同社の臨床段階における薬品候補は「Pimavanserin」、「Alpha Adrenergic Agonists」、「Muscarinic Agonist」と「AM-831」を含む。  アカディア・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。神経および関連中枢神経系疾患に対する治療薬に焦点を当て、主に、パ―キンソン病、精神分裂病、神経痛、アルツハイマ―病などの治療に関係する治療薬候補を開発する。本社は、カリフォルニア州サンディエゴ。   Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
本社所在地 3611 Valley Centre Drive Suite 300 San Diego CA 92130 USA
代表者氏名 Stephen R. Biggar スティーブン・R・ビガール
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-558-2871
設立年月日 34151
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 425人
url www.acadia-pharm.com
nasdaq_url https://www.nasdaq.com/symbol/acad
adr_tso
EBITDA EBITDA(百万ドル) -251.19800
終値(lastsale) 21.11
時価総額(marketcap) 2638891922.53
時価総額 時価総額(百万ドル) 2645.142
売上高 売上高(百万ドル) 185.07100
企業価値(EV) 企業価値(EV)(百万ドル) 2388.287
当期純利益 当期純利益(百万ドル) -182.79200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ACADIA Pharmaceuticals Inc. revenues increased from $45.8M to $105.9M. Net loss decreased 24% to $117.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income net increase of 25% to $2.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.27 to -$0.94.

 ACADのテクニカル分析


 ACADのニュース

   Bluebird bio Seeks Back-to-Back Nods, ''Go'' or ''No-Go'' For Revance''s Botox Rival, Amylyx'' Twin Hurdles And More: September''s Key PDUFA Catalysts Biotech Investors Must Know  2022/08/31 18:52:35 Benzinga
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. New molecular entity approvals drew a blank in August. NMEs are those active moieties that have not been previously approved by the FDA. This should be a cause of concern, as NME approvals are considered a measure of innovation in drug research. The fortunate ones that could take their drugs past the finish line included bluebird bio, Inc. (NASDAQ: BLUE ), Johnson & Johnson (NYSE: JNJ ), and Axsome Therapeutics, Inc. (NASDAQ: AXSM ). ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD ) faced rejection for expanding the label of its Nuplazid to be able to treat Alzheimer’s disease psychosis. CorMedix, Inc.’s (NASDAQ: CRMD ) defencath application was shot down by the FDA for a second time. The review period for Amicus Therapeutics, Inc.’s (NASDAQ: FOLD ) Pompe disease treatment was extended. The Prescription Drug User Fee Act, or PDUFA, date is the period by which the FDA is required to rule on an application submitted by a sponsor company.
   Was anything negative for ACADIA Pharmaceuticals Inc. (ACAD) stock last session?  2022/08/30 14:40:00 US Post News
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) marked $16.47 per share on Monday, down from a previous closing price of $16.53. While ACADIA Pharmaceuticals Inc. has underperformed by -0.36%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACAD fell by -1.26%, with highs and lows ranging from $28.06 to […]
   ACADIA Pharmaceuticals''s Return On Capital Employed Insights  2022/08/29 13:55:27 Benzinga
According to Benzinga Pro data, during Q2, ACADIA Pharmaceuticals (NASDAQ: ACAD ) posted sales of $134.56 million. Earnings were up 69.92%, but ACADIA Pharmaceuticals still reported an overall loss of $34.01 million. In Q1, ACADIA Pharmaceuticals brought in $115.47 million in sales but lost $113.06 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com
   A stock that deserves closer examination: ACADIA Pharmaceuticals Inc. (ACAD)  2022/08/24 11:00:00 US Post News
In Tuesday’s session, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) marked $16.88 per share, up from $16.75 in the previous session. While ACADIA Pharmaceuticals Inc. has overperformed by 0.78%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACAD rose by 1.20%, with highs and lows ranging from $28.06 to […]
   ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees  2022/08/09 12:33:08 Benzinga
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) reported upbeat results for its second quarter after the closing bell on Monday. ACADIA Pharmaceuticals posted a quarterly loss of $0.21 per share on sales of $134.56 million. Analysts, however, were expecting a loss of $0.25 per share on sales of $130.43 million. ACAD shares fell 3.7% to $16.01 in pre-market trading. Several analysts made changes to their … Full story available on Benzinga.com
   Acadia shares to spike with a positive AdCom vote for pimavanserin next month - Citi  2022/05/19 16:33:30 Seeking Alpha
As neurology-focused biotech Acadia Pharma (ACAD) prepares for an AdCom meeting next month on its marketing application for pimavanserin in Alzheimer’s disease psychosis ((ADP)),…
   ACADIA Pharmaceuticals: No Upturn in Sight  2022/05/18 13:24:13 TipRanks
ACADIA Pharmaceuticals (ACAD) is a biotechnology developer of breakthrough therapies in neuroscience. Specifically, ACADIA markets Nuplazid for hallucinations and delusions associated with Parkinson''s disease. Nuplazid is an antipsychotic, the first and only drug (the company says) approved to treat psychosis in schizophrenia and other psychotic disorders. As more schizophrenic patients are enrolled in a Phase 3 trial evaluating Nuplazid for the negative symptoms of this serious mental illness, the company is working to develop Nuplazid for Alzheimer''s psychosis. ACADIA is also developing a treatment for patients with Rett syndrome.
   Parkinson''s Disease (PD) Drugs market - 37% of Growth to Originate from Europe | Evolving Opportunities with AbbVie Inc. & Amneal Pharmaceuticals Inc. | Technavio  2022/05/18 06:30:00 Benzinga
NEW YORK , May 18, 2022 /PRNewswire/ -- The Parkinson''s disease (PD) drugs market size is expected to grow by USD 1.57 billion from 2019 to 2024 at a CAGR of 6% as per the latest market report by Technavio. 37% of the market''s growth will originate from Europe during the forecast period. Germany , Italy , the UK, and Spain are the key markets for Parkinson''s disease (PD) drugs in Europe . Market growth in this region will be faster than the market''s growth in the Asian and North American regions. The strong prevalence of PD and the easy availability of multiple approved drugs will facilitate the Parkinson''s disease (PD) drug market growth in Europe over the forecast period. For more insights on the market share of various regions - Download a sample report in MINUTES Read the 120-page report with TOC on "Parkinson''s Disease (PD) Drugs Market Analysis Report by D rug class (DA and levodopa-carbidopa, MAO inhibitors, AChE inhibitors, glutamate inhibitors, and others) and Geography ( Europe , North America , Asia , and ROW), and the Segment Forecasts,2020-2024".
   ACADIA Pharmaceuticals Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:ACAD)  2022/05/06 02:25:59 Seeking Alpha
The following slide deck was published by ACADIA Pharmaceuticals Inc.
   ACADIA Pharmaceuticals Inc. (ACAD) CEO Stephen Davis on Q1 2022 Results - Earnings Call Transcript  2022/05/05 02:35:22 Seeking Alpha
ACADIA Pharmaceuticals Inc. (NASDAQ:NASDAQ:ACAD) Q1 2022 Earnings Conference Call May 04, 2022, 04:30 PM ET Company Participants Mark Johnson - VP, IR Stephen Davis - CEO Brendan Teehan -…
   ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q4 2021 Results - Earnings Call Transcript  2022/03/01 03:00:03 Seeking Alpha
   Acadia Pharma down 6% after hours after earnings misses  2022/02/28 21:52:02 Seeking Alpha
Shares of Acadia Pharma (ACAD) are down ~6% in post-market trading after its Q4 2021 results missed on the top and bottom lines.Net loss narrowed in the quarter 36% to ~$43.1M
   ACADIA Pharma GAAP EPS of -$0.27 misses by $0.04, revenue of $130.8M misses by $4.64M  2022/02/28 21:10:56 Seeking Alpha
ACADIA Pharma press release (ACAD): Q4 GAAP EPS of -$0.27 misses by $0.04.Revenue of $130.8M (+8.1% Y/Y) misses by $4.64M.2022 Financial Guidance: NUPLAZID net sales guidance…
   Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results  2022/02/28 21:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2021. “Acadia delivered strong fourth quarter and full year results with an increase in net sales of 10 percent year-over-year, driven by growth in both NUPLAZID prescriptions and market share,” said Steve Davis, Chief Executive Officer. “We recently resubmitted our sNDA for pimavanserin for Alzheimer’s disease psychosis to the FDA. In
   ACADIA Pharma Q4 2021 Earnings Preview (NASDAQ:ACAD)  2022/02/25 22:35:01 Seeking Alpha
ACADIA Pharma (NASDAQ:ACAD) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.24 and the consensus Revenue…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アカディア・ファ―マシュ―ティカルズ ACAD ACADIA Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)